Metraipolis › archive › dc_45be9ad09362

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B — Europe PMC PMID:40327725

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40327725
DOI
10.1371/journal.pcbi.1012322
License (as archived)
CC0-1.0
Archived
2026-10-06T11:29:05.713Z
SHA-256 of the archived text
d58005f3a7b06773a1d202e83f4749c58ef39f613b82d0beb828f0dcdb4b8d8a
Stable URL of this page
https://metraipolis.com/documento/dc_45be9ad09362

How to cite

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B — Europe PMC PMID:40327725 — Europe PMC (en), https://europepmc.org/article/MED/40327725 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_45be9ad09362 (Metraipolis archive dc_45be9ad09362, sha256 d58005f3a7b06773a1d202e83f4749c58ef39f613b82d0beb828f0dcdb4b8d8a)
BibTeX
@misc{dc45be9ad09362,
  title = {A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B — Europe PMC PMID:40327725},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40327725},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_45be9ad09362; sha256 d58005f3a7b06773a1d202e83f4749c58ef39f613b82d0beb828f0dcdb4b8d8a},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40327725. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Chronic hepatitis B virus (HBV) infection is strongly associated with increased risk of liver cancer and cirrhosis. While existing treatments effectively inhibit the HBV life cycle, viral rebound frequently occurs following treatment interruption. Consequently, functional cure rates of chronic HBV infection remain low and there is increased interest in a novel treatment modality, capsid assembly modulators (CAMs). Here, we develop a multiscale mathematical model of CAM treatment in chronic HBV infection. By fitting the model to participant data from a phase I trial of the first-generation CAM vebicorvir, we estimate the drug's dose-dependent effectiveness and identify the physiological mechanisms that drive the observed biphasic decline in HBV DNA and RNA, and mechanistic differences between HBeAg-positive and negative infection. Finally, we demonstrate analytically and numerically that the relative change of HBV RNA more accurately reflects the antiviral effectiveness of a CAM than the relative change in HBV DNA.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2025 (prima pubblicazione 2025-05-06).
Identificativi: PMID 40327725 · PMCID PMC12121926 · DOI 10.1371/journal.pcbi.1012322.
Descrittori MeSH principali: Hepatitis B virus; Capsid; Hepatitis B, Chronic; Antiviral Agents; Virus Assembly; Models, Biological.
Pagina: https://europepmc.org/article/MED/40327725 — https://doi.org/10.1371/journal.pcbi.1012322. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:52:29.942Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.